Overview

• Johnson & Johnson delivered adjusted Q2 EPS of $2.77 and $23.74 billion in revenue, surpassing consensus estimates of $2.68 per share and $22.84 billion.
• The company lifted its 2025 sales forecast to $93.2–93.6 billion and raised adjusted EPS guidance to $10.80–$10.90 per share.
• It reduced its tariff-related cost outlook to $200 million from $400 million after the U.S. government paused levies on China.
• Strong demand for Darzalex and a 6.1% increase in medtech sales powered the earnings beat, while pharmaceuticals revenue topped $15.2 billion.
• Shares jumped more than 6% following the results, and investors await a Q3 update on the pending talc litigation settlement.